Designing, Formulation and Evaluation of Lercanidipine-Loaded Solid Lipid Nanoparticles for Enhancing Bioavailability for Anti-hypertensive action

Abstract:Lercanidipine, a dihydropyridine calcium channel blocker, is effective in hypertension management but suffers from poor aqueous solubility and low bioavailability. This study developed and optimized solid lipid nanoparticles (SLNs) to enhance Lercanidipine’s bioavailability. Preformulation studies confirmed drug-excipient compatibility, while a 3² factorial design optimized lipid and surfactant ratios. SLNs were characterized for particle size, entrapment efficiency (DEE), morphology, in vitro release, and stability. Fourier-transform infrared spectroscopy (FTIR) and high-performance liquid chromatography (HPLC) ensured structural integrity and quantification. The optimized formulation (F3) achieved a particle size of 155 ± 12 nm, DEE of 93 ± 2%, and controlled release of 76% over 12 hours. Stability studies confirmed robustness over 90 days. These findings suggest SLNs as a promising carrier for improving Lercanidipine’s therapeutic efficacy.